Skip to main content

Table 4 Treatment of patients with COVID-19

From: Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

 Total (n = 91)Severe (30, 33.0%)Mild (61, 67.0%)P value
glucocorticoid79/91 (86.8%)25/30 (83.3%)54/61 (88.5%)0.399
antiviral therapy81/91 (89.0%)24/30 (80.0%)57/61 (93.4%)0.061
oseltamivir24/91 (26.4%)6/30 (20.0%)18/61 (29.5%)0.240
lopinavir/ritonavir64/91 (60.3%)16/30 (53.3%)48/61 (78.7%)0.013
umifenovir53/91 (58.2%)22/30 (73.3%)31/61 (50.8%)0.033
antibacterial therapy90/91 (98.9%)30/30 (100.0%)60/61 (98.4%)0.670
cephalosporin27/91 (29.7%)12/30 (40.0%)15/61 (24.6%)0.103
fluoroquinolones84/91 (92.3%)27/30 (90.0%)57/61 (93.4%)0.421
carbapenems2/91 (2.2%)2/30 (6.7%)0 (0)0.059
immunoglobulin35/91 (38.5%)16/30 (53.3%)19/61 (31.2%)0.035
oxygen therapy29/91 (31.9%)17/30 (56.7%)12/61 (19.7%)0.001
mechanical ventilation5/91 (5.5%)5/30 (16.7%)0 (0)0.003
CRRT3/91 (3.3%)3/30 (10.0%)0 (0)0.033
  1. CRRT Continuous renal replacement therapy